3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
3
Melanoma
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphatic Metastasis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Anus Neoplasms
1
Interventions
Carboplatin
156
Paclitaxel
154
Bevacizumab
96
Cyclophosphamide
61
Gemcitabine
46
olaparib
45
Cisplatin
45
Topotecan
44
niraparib
40
liposomal doxorubicin
40
pembrolizumab
38
Surveys and Questionnaires
33
Filgrastim
31
Hyperthermic Intraperitoneal Chemotherapy
29
Docetaxel
27
Taxes
25
Blood Specimen Collection
24
fludarabine
23
Drug Therapy
23
Cytoreduction Surgical Procedures
23
Peripheral Blood Stem Cell Transplantation
21
Etoposide
21
Doxorubicin
21
Magnetic Resonance Spectroscopy
20
durvalumab
17
Specimen Handling
17
Albumin-Bound Paclitaxel
17
Immunoglobulin G
15
Disulfides
15
Letrozole
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Ovarian Neoplasms
×
Technetium-99
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled